Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | terminated | Phase 2 | 2 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Early Phase 1 | 46 | AmgenINDUSTRY | 3 | Sep 1, 2023 | clinicaltrials |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | terminated | Phase 2 | 12 | Hackensack Meridian HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | terminated | Phase 2 | 2 | Andrew Yee, MDOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse(OPERA-PLRG10) | terminated | Phase 2 | 1 | Polish Lymphoma Research GroupNETWORK | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | terminated | Phase 3 | 96 | Gilead SciencesINDUSTRY | 10 | Aug 14, 2023 | clinicaltrials |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | terminated | Phase 1 | 9 | AstraZenecaINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05501171 | Psychological Mobile App for Patients With AML | terminated | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02134782 | Yoga Fatigue Study | terminated | N/A | 125 | The Hospital for Sick ChildrenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | terminated | Phase 2 | 34 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | terminated | Phase 2 | 41 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05244070 | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 5 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | terminated | Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT00003910 | Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia | terminated | Phase 2 | 59 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00335140 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | terminated | Phase 2 | 26 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04081298 | eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors(MiVSEEV) | terminated | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00060346 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00070291 | Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma | terminated | Phase 2 | 4 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01390584 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | terminated | Phase 2 | 6 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | terminated | Phase 1 | 12 | University of WashingtonOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00057954 | Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma | terminated | Phase 2 | 6 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | terminated | Phase 2 | 31 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01307605 | Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | terminated | Phase 2 | 154 | Swiss Cancer InstituteOTHER | 3 | Jun 27, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | terminated | Early Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | terminated | Phase 2 | 116 | TG Therapeutics, Inc.INDUSTRY | 4 | Jun 22, 2023 | clinicaltrials |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | terminated | Phase 2 | 1 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT | terminated | Phase 1 | 11 | Mana TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05645133 | QPlus Pediatric Reference Interval | terminated | — | 93 | HemoSonics LLCINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | terminated | Phase 1 | 12 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 6 | Jun 13, 2023 | clinicaltrials |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma | terminated | Phase 2 | 1 | Amit VermaOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma(LIGHTHOUSE) | terminated | Phase 3 | 54 | Oncopeptides ABINDUSTRY | 11 | Jun 8, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | terminated | Phase 3 | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04186637 | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies(NEON-1) | terminated | Phase 1 | 62 | Alpine Immune Sciences, Inc.INDUSTRY | 2 | Jun 5, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Sep 14, 2023source: clinicaltrials